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To the Editor:
We have read with great inter-
est the article “Cisplatin versus 
Carboplatin-Based Regimens for the 
Treatment of Patients with Metastatic 
Lung Cancer. An Analysis of Veterans 
Health Administration Data” reported 
by Santana-Davila and colleagues in 
Journal of Thoracic oncology (May 
2014).1 We are impressed that the 
authors presented a great retrospec-
tive study with competent data and 
accurate statistical analysis. However, 
selection bias obviously existed in the 
study, as they stated in the discussion 
part. First, although the study sample 
is large enough, which included 4352 
patients, only 291 (6.7%) patients in 
the cisplatin group. Second, the inho-
mogeneity of combined chemothera-
peutic agents may affect the overall 
survival.2 Approximately 30% of 
patients treated with cisplatin were 
administered with etoposide, whereas 
only 1.7% of patients in the carbo-
platin group. Third, bevacizumab was 
used more in carboplatin group (5.9%) 
than in cisplatin group (0.7%). When 
added to paclitaxel/carboplatin, it 
can improve survival in previously 
untreated patients with advanced non-
squamous non–small-cell lung cancer 
(NSCLC).3 In addition, the authors did 
not mention the post-study treatment. 
During the last decade, many advances 
have been made in the treatment of 
advanced NSCLC, e.g., targeted ther-
apy. Further treatment after first-line 
chemotherapy may also impact on 
overall survival.
As we know, good-designed ran-
domized clinical trials provide strong 
evidence that may change the current 
treatment pattern. Rosell and colleagues 
conducted direct comparison of pacli-
taxel/carboplatin versus paclitaxel/cispl-
atin in advanced NSCLC.4 The baseline 
patient’s characteristics and follow-up 
therapy were well balanced between 
the two treatment arms. The overall 
response rate in the two arms of pacli-
taxel/carboplatin and paclitaxel/cis-
platin was 28% and 25%, respectively, 
which was similar. However, patients 
received paclitaxel/cisplatin had the sig-
nificantly longer median survival (9.8 
months) than paclitaxel/carboplatin (8.2 
months). This is confirmed by an indi-
vidual patient data meta-analysis.5 In 
patients with non-squamous histology, 
cisplatin-based chemotherapy prolonged 
survival in comparison to carboplatin-
based chemotherapy (hazard ratio = 
1.12, 95% confidence interval = 1.01–
1.23), but not in squamous histology. In 
our opinion, there are enough evidences 
to support use of cisplatin in advanced 
NSCLC, especially in non-squamous 
histology. In our daily clinical practice, 
for eligible patients with non-squamous 
NSCLC, we would like to recommend 
cisplatin preferentially.
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To the Editor:
We congratulate Shi et al1 for 
their prospective multinational, epide-
miological study of epidermal growth 
factor receptor (EGFR) mutations in 
patients from Asia with newly diag-
nosed advanced lung adenocarcinoma 
(PIONEER study) which showed that 
51.4% of tumors from 1450 patients 
had a positive EGFR mutation status. 
Although the frequency of EGFR muta-
tions was 50% or higher for patients 
of East Asian ethnicities (Vietnamese, 
64.2%; Thai, 53.8%; Chinese, 51.8%, 
and Filipino, 50.0%), it was significantly 
lower for Indian patients (21.9%). Our 
study on Malaysian patients who were 
of three major ethnicities, ie, Chinese, 
Malay, and Indian, showed that 39.5% 
of tumors from 812 patients with 
advanced adenocarcinoma were EGFR 
mutation positive.2 The frequency of 
EGFR mutations was not significantly 
different between our Chinese (40.8% 
of 517 patients), Malay (37.2% of 239 
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To the Editor:
We read with keen interest the 
article by Chiu et al1 on the clinical 
characteristics and treatment outcomes 
of patients with lung adenocarcino-
mas with discrepant EGFR mutation 
testing results by polymerase chain 
reaction (PCR)-direct sequencing and 
the more sensitive mutant allele-spe-
cific real-time PCR-based Scorpion 
Amplification Refractory Mutation 
System (ARMS) which showed that 
21.5% of 130 tumours which were 
EGFR mutation-negative by direct 
sequencing were found to have EGFR 
mutations by the latter assay.
patients), and Indian (33.3% of 39 
patients) patients. Our study was the 
first report on the prevalence of EGFR 
mutation in patients of Malay ethnicity 
that was not covered by the PIONEER 
study. The Malays constitute a sizeable 
population in Southeast Asia includ-
ing Malaysia, Indonesia, parts of the 
Philippines, and parts of Thailand.
We could have overestimated the 
frequency of EGFR mutations in our 
patients of Indian ethnicity because of 
the small number of Indian patients 
compared with the PIONEER study1 
with 73 patients of Indian ethnicity and a 
study in India3 where 23% of adenocar-
cinomas from 907 patients were EGFR 
mutation positive. The frequency of 
EGFR mutation among Indian patients 
with adenocarcinoma in the PIONEER 
study1 and the study in India3 which is 
intermediate between that of East Asian 
patients (approximately 50–64%)1 and 
Western patients (approximately 20%)4 
is probably because of an admixture of 
genetic influence from Middle Eastern, 
Central Asian, and European ancestors 
on the modern-day Indian population 
that may confer differential susceptibil-
ity to somatic mutations in EGFR.5
Similar to the findings by the 
PIONEER study,1 EGFR mutations 
were significantly more frequent among 
our female than in male patients (52.5% 
versus 27.8%) and in our patients who 
had never smoked compared with those 
who had smoked (54.8% versus 20.7%).2 
We also observed that a never smoking 
status was the independent predictor of 
EGFR mutation positivity and female 
gender was not a significant predictor 
after adjusting for smoking status.2
We concur with Shi et al1 that the 
observed high frequency of EGFR muta-
tions in Asian patients including those of 
Indian ethnicity compared with Caucasian 
populations suggests that mutation test-
ing should be considered for all Asian 
patients with advanced lung adenocarci-
noma, even in males and smokers.
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In our study involving 812 
patients with lung adenocarcinoma 
from 2009 to 2011,2 bidirectional 
sequencing3,4 was initially used to 
detect EGFR mutations in formalin-
fixed, paraffin-embedded tumour 
biopsy specimens from November 2009 
to August 2011 but the method was 
later switched to real-time PCR (EGFR 
RGQ PCR Kit; QIAGEN, Manchester, 
United Kingdom). The bidirectional 
sequencing method used primers and 
PCR conditions as described by Lynch 
et al.3 Uncloned PCR fragments were 
purified and subjected to sequencing 
before being analyzed for the presence 
of mutation in both sense and antisense 
directions. In real-time-PCR, mutations 
of EGFR (exons 18, 19, 20, and 21) 
genes were detected by ARMS prim-
ers and Scorpion detection technology 
on Rotor-Gene platform (QIAGEN). 
The direct sequencing method was used 
for EGFR mutation detection in 416 
(51.2%) of our tumor samples. A higher 
percentage of tumours were tested 
EGFR mutation-positive by Scorpion 
ARMS (170 [42.9%] of 396 tumours) 
than by direct sequencing (151 [36.3%] 
of 416 tumours) but the difference was 
not statistically significant (p = 0.053). 
However, although we did not perform 
a head-to-head comparison of the two 
methods, our results also suggested 
that allele-specific, real-time PCR was 
more sensitive than direct sequencing 
in detecting EGFR mutations, and this 
may partly explain the lower EGFR 
mutation frequency of 39.5% in our 
patients with adenocarcinoma com-
pared with other East Asian ethnici-
ties (Vietnamese, 64.2%; Thai, 53.8%; 
Chinese, 51.8%, and Filipino, 50.0%) as 
shown by the PIONEER study in which 
Scorpion ARMS was used.5 In our 
study, exon 19 mutations (in 23.5% of 
tumours) were the most common muta-
tions followed by exon 21 mutations (in 
14.9% of tumours).2 Interestingly, exon 
19 mutations were significantly more 
frequently detected by Scorpion ARMS 
(108 [27.3%] of 396 tumours) than by 
direct sequencing (83 [20.0%] of 416 
tumours; p = 0.018) in our study.2
We agree with Chiu et al1 that 
direct sequencing may under-detect 
EGFR mutations in a significant propor-
tions of lung adenocarcinoma patients 
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